Company Overview - Agenus (AGEN) shares increased by 19.3% to $7.06 in the last trading session, with a notable trading volume, and have gained 22.8% over the past four weeks [1][2] Clinical Data - The company announced positive clinical results for its combination therapy of botensilimab and balstilimab (BOT/BAL) in patients with microsatellite-stable metastatic colorectal cancer, showing a two-year survival rate of 42% in an expanded cohort of 123 patients, with a median overall survival of 21 months [2] Financial Expectations - Agenus is projected to report a quarterly loss of $0.78 per share, reflecting a year-over-year increase of 69.1%, with expected revenues of $25.03 million, up 6.5% from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Agenus is part of the Zacks Medical - Biomedical and Genetics industry, where Illumina (ILMN) closed 0.8% lower at $99.25, having returned 13.5% in the past month [5] - Illumina's consensus EPS estimate for its upcoming report is $1.02, representing a year-over-year change of 183.3%, and it currently holds a Zacks Rank of 3 (Hold) [6]